Business
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are b
About this update from Fractyl Health, Inc.
[{"type":"image","alt":"Fractyl Health, Inc.","displaySize":"","headline":null,"caption":"Fractyl Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/grE4KlKD7t64vNihlXguCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5","width":300,"height":104}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":349,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/082b7d9e2ca2120142213dc552b9159a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rTForaZfTnJ56Z3wW1Iang--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/082b7d9e2ca2120142213dc552b9159a","width":349,"height":133}}},{"type":"text","content":"Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock ","length":85,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are being offered by Fractyl. The gross proceeds from the offering to Fractyl are expected to be approximately $60 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.","length":724,"tagName":"p"},{"type":"text","content":"BofA Securities and Evercore ISI are acting as joint book-running managers and Ladenburg Thalmann is acting as lead manager for the underwritten offering.","length":154,"tagName":"p"},{"type":"text","content":"A shelf registration statement relating to the securities offered in the offering described above was filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025, and declared effective by the SEC on March 18,...